1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

If you're willing to be patient, biotech stocks can offer significant upside, even if you only invest a relatively small amount, like $1,000. In that vein, Madrigal Pharmaceuticals (NASDAQ: MDGL) has a lot to offer. Between its recently launched new drug and being the first in its market, it has a long runway for growth. Here's why it's worth an investment today, provided that you're willing to hold on to your shares for at least a few years.Madrigal makes a medicine called Rezdiffra, which is currently the only approved treatment for metabolic-associated steatohepatitis (MASH, formerly known as NASH) in patients with moderate to advanced fibrosis (scarring) of the liver. Right now, its target market comprises the roughly 315,000 patients in the U.S. with MASH who are already diagnosed and in the care of specialists, but its addressable market could one day be as large as the entire population of 1.5 million people in the U.S. who have some form of MASH.Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no revenue at all, and it's likely that its revenue will continue to rise for at least a couple of years as its commercial rollout continues.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool